The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for MCL?
Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses the benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma (MCL). Previous data was varied, as the MAINTAIN trial (NCT00877214) showed no overall survival (OS) or progression-free survival (PFS) benefit with rituximab maintenance, but several small cohort retrospective studies had. Dr Wang presents the results from a large observational multi-center study in a cohort of patients who had not progressed three months after the end of bendamustine-rituximab therapy. At the five-year follow-up, rituximab maintenance was associated with improved OS and event-free survival (EFS), statistically significant in patients achieving a complete response (CR). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
